Physician profile
Mehran Salek
NPI 1558833830
$12,665.20
in general payments reported to CMS, 2019-2025
13 companies · $139 in 2025
The $139 reported for 2025 was less than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,075 · 2020: $6,905 · 2022: $2,893 · 2023: $161 · 2024: $492 · 2025: $139.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $792.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $792.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $11,858.25 | 2019-2022 | |
| Inari Medical, INC. | $449.75 | 2024-2025 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Organon LLC | $69.67 | 2023 | Nexplanon |
| Abbvie INC. | $51.40 | 2023-2024 | Vraylar |
| Becton, Dickinson and Company | $51.23 | 2023-2024 | Lutonix Drug Coated Balloon, Bd Onclarity |
| Astellas Pharma US INC | $38.11 | 2023 | Veozah |
| Exact Sciences Corporation | $34.39 | 2025 | Cologuard Collection Kit |
| Optumhealth Care Solutions, LLC | $30.89 | 2025 | Eitan Medical, Vivify Health Care Team Portal 001 |
| Intra-Sana Laboratories | $20.29 | 2025 | Reltone 200 Mg, Glycate, Reltone 400 Mg |
| Indivior INC. | $17.79 | 2025 | Sublocade |
| Sage Therapeutics, LLC | $15.12 | 2025 | Zurzuvae |
| Daiichi Sankyo INC. | $14.85 | 2019 | |
| Merck Sharp & Dohme LLC | $13.46 | 2024 | Gardasil, Gardasil 9 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mehran Salek listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.